Researchers from Rice University and Baylor College of Medicine have demonstrated a groundbreaking treatment that eradicates ...

Population and animal studies suggested it could treat cancer, but the clinical trials were a bust. Here’s what happened and ...

Drug development in oncology is historically challenging, exhibiting a very high attrition rate, with low rates of approval for novel treatments when compared to other therapeutic areas. At present, ...

Promising results from the anti–LAG-3/anti–PD-1 combo for melanoma, FDA approval of inavolisib for PIK3CA-mutant breast cancer, significant survival benefits from talazoparib and enzalutamide in ...

Among the many wonder products out there on the market, there is a type that inspires equal parts fascination and scepticism ...

Bacteria-based therapies represent an exciting breakthrough in cancer treatment, harnessing their remarkable ability to specifically target and attack tumors. To fully harness the potential of this ...

The regulation and remodeling of the tumor microenvironment (TME) are closely associated with how cancers typically progress ...

In an effort to fight counterfeiting of costly cancer medicines which put the lives of patients at risk, the Drugs Technical Advisory Board (DTAB), the body that advises the Central and state ...

The multidisciplinary care plan ONCORAL promptly identified drug-related problems in patients receiving oral anticancer therapy.

Forty years after the Hatch-Waxman Act created a market for affordable generic versions of prescription medications, ...

Barzilai, who is 68, says he is confident in metformin’s anti-aging ability and already takes the drug himself. Others, mindful of what happened with cancer, are more circumspect. Pollak says ...